NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Recruiting · NCT07439744 · Interventional (participants receive a specific treatment) · Lead sponsor: National Science and Technology Council, Taiwan
View the official record on ClinicalTrials.gov →Interventions studied
Eicosapentaenoic acid (omega-3 fatty acid)Placebo
What this trial is about
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Who can take part
Age range
18 Years to 54 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Major depressive disorder.
- Antidepressant drug-free.
Exclusion criteria
- Schizophrenia
- Mania
- Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Alcohol or drug abuse/dependence (except for nicotine)
- Active suicidal ideation
- Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement
Where it is running
1 location listed.
- Mind Body Interface Research Center (MBI Lab & Care) - Taichung, Taichung, Taiwan